191 related articles for article (PubMed ID: 37153748)
21. Enhancing Radioiodine Incorporation in
Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
[No Abstract] [Full Text] [Related]
22. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
23. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
[TBL] [Abstract][Full Text] [Related]
24. An Acid-Sensitive Nanofiber Conjugate Based on a Short Aromatic Peptide for Targeted Delivery of Doxorubicin in Liver Cancer.
Liang J; Guo R; Xuan M; Sun Q; Wu W
Int J Nanomedicine; 2022; 17():2961-2973. PubMed ID: 35818401
[TBL] [Abstract][Full Text] [Related]
25. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Falchook GS; Millward M; Hong D; Naing A; Piha-Paul S; Waguespack SG; Cabanillas ME; Sherman SI; Ma B; Curtis M; Goodman V; Kurzrock R
Thyroid; 2015 Jan; 25(1):71-7. PubMed ID: 25285888
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract][Full Text] [Related]
27. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
28. Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer.
Murugan AK; Qasem E; Al-Hindi H; Shi Y; Alzahrani AS
J Transl Med; 2016 Jul; 14(1):204. PubMed ID: 27387551
[TBL] [Abstract][Full Text] [Related]
29. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
30. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
31. Local delivery of doxorubicin through supramolecular peptide amphiphile nanofiber gels.
Cinar G; Ozdemir A; Hamsici S; Gunay G; Dana A; Tekinay AB; Guler MO
Biomater Sci; 2016 Dec; 5(1):67-76. PubMed ID: 27819087
[TBL] [Abstract][Full Text] [Related]
32. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.
Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
[TBL] [Abstract][Full Text] [Related]
33. THE RELATIONSHIP OF BRAF
Santhanam P; Khthir R; Solnes LB; Ladenson PW
Endocr Pract; 2018 Jan; 24(1):21-26. PubMed ID: 29144823
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
35. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
36. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAF(V600E) Mutation.
Li J; Yang T; Zhao T; Liang J; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):346-50. PubMed ID: 27544995
[TBL] [Abstract][Full Text] [Related]
38. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
39. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
40. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
